Cuprina (CUPR) said Monday it completed construction of its in-vitro fertilization media production facility in Singapore and obtained ISO 13485 certification and a dealer license for the site on April 6.
The ISO certification was issued by the United Kingdom Accreditation Service, while the dealer license was granted by the Singapore Health Sciences Authority.
Developed in collaboration with medtech company Ferti-Craft, the facility is expected to produce 14 stock keeping units of IVF media containing nutrients, electrolytes, amino acids, and other materials required to stimulate fertilization of sperm and ovum in-vitro.
Cuprina said it will work with Ferti-Craft to prepare and submit regulatory dossiers to HSA to seek approval for the 14 SKUs.
Under the agreement, Ferti-Craft will be responsible for securing documentation and testing certificates required by HSA, managing raw material sourcing and logistics, and contributing intellectual property and technical expertise in assisted reproductive technology.
The companies expect the facility to begin commercial production by Q4 2026, pending regulatory approval. Initial sales are expected to focus on Singapore, with expansion into select ASEAN countries, the Middle East, and other global markets to follow.
Shares of Cuprina were down 6% in recent trading.
Price: 5.80, Change: -0.37, Percent Change: -6.00
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。